Case-control study of diabetes mellitus in HIV-infected patients

被引:18
作者
Yoon, C
Gulick, RM
Hoover, DR
Vaamonde, CM
Glesby, MJ
机构
[1] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA
[2] Rutgers State Univ, Hlth Care Policy & Aging Res, Dept Stat, Piscataway, NJ USA
[3] Rutgers State Univ, Hlth Care Policy & Aging Res, Inst Hlth, Piscataway, NJ USA
关键词
diabetes mellitus; hyperglycemia; risk factors; metabolic complications of HIV infection; hepatitis C virus;
D O I
10.1097/01.qai.0000137373.26438.18
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Diabetes mellitus (DM) is more prevalent among patients with HIV infection. Besides protease inhibitors (PIs), other factors may contribute to the development of DM. Objective: To assess characteristics associated with the development of DM in HIV-infected persons. Methods: We conducted a case-control study in an urban HIV clinic among patients with incident DM (49 cases) matched to 2 controls (n = 98) on age 5 years, race, sex, and length of clinic follow-up. There was a second set of unmatched controls (n = 196). Results: Compared with matched controls, case patients had higher mean body mass index (BMI; 30.0 vs. 25.3 kg/m(2), matched odds ratio [OR] = 1.20; P < 0.001), higher alanine aminotransferase (ALT; 66 vs. 44 U/L, OR = 1.12 per 10 U/L; P = 0.013), and stronger family history of DM (50% vs. 29%, OR = 3.30; P = 0.009). Hepatitic C virus coinfection and PI use were not significant factors. In unmatched controls, there was no significant difference in age, sex, or ethnicity. In multivariate analyses, BMI (OR = 1.13 per kg/m(2); P = 0.012), family history (OR = 5.55; P = 0.014), and ALT (OR = 1.16; P = 0.012) were associated with DM. Conclusion: These findings suggest a complex interaction among genetic factors, body composition, and liver injury in the pathogenesis of DM in HIV-infected patients.
引用
收藏
页码:1464 / 1469
页数:6
相关论文
共 42 条
[1]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[2]  
[Anonymous], 2000, DIABETES CARE S1, V23, pS20
[3]   Diabetic dyslipidaemia - Current treatment recommendations [J].
Best, JD ;
O'Neal, DN .
DRUGS, 2000, 59 (05) :1101-1111
[4]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[5]   HIV protease inhibitor-related lipodystrophy syndrome [J].
Carr, A .
CLINICAL INFECTIOUS DISEASES, 2000, 30 :S135-S142
[6]   Alanine Aminotransferase Levels Predict Insulin Resistance in HIV Lipodystrophy [J].
Chung, Raymond T. ;
Casson, Deborah R. ;
Murray, Gisela ;
Song, Sunbin ;
Grinspoon, Steven ;
Hadigan, Colleen .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (05) :534-536
[7]  
CURRIER JS, 2002, 9 C RETR OPP INF SEA
[8]   PATHOGENESIS OF NIDDM - A BALANCED OVERVIEW [J].
DEFRONZO, RA ;
BONADONNA, RC ;
FERRANNINI, E .
DIABETES CARE, 1992, 15 (03) :318-368
[9]  
Dever LL, 2000, ANN PHARMACOTHER, V34, P580
[10]   Protease inhibitor-associated hyperglycaemia [J].
Dube, MP ;
Johnson, DL ;
Currier, JS ;
Leedom, JM .
LANCET, 1997, 350 (9079) :713-714